iShares Biotechnology ETF $IBB Shares Acquired by Aptus Capital Advisors LLC

Posted by George Bondi on Jun 14th, 2026

Aptus Capital Advisors LLC lifted its holdings in shares of iShares Biotechnology ETF (NASDAQ:IBB – Free Report) by 9,664.1% during the 4th quarter, Holdings Channel.com reports. The firm owned 204,362 shares of the financial services provider’s stock after acquiring an additional 202,269 shares during the period. Aptus Capital Advisors LLC’s holdings in iShares Biotechnology ETF were worth $34,490,000 at the end of the most recent quarter.

Several other hedge funds have also made changes to their positions in the business. Arete Wealth Advisors LLC boosted its holdings in shares of iShares Biotechnology ETF by 44.1% during the fourth quarter. Arete Wealth Advisors LLC now owns 2,696 shares of the financial services provider’s stock worth $455,000 after purchasing an additional 825 shares during the last quarter. Cordoba Advisory Partners LLC acquired a new stake in shares of iShares Biotechnology ETF during the fourth quarter worth $498,000. Kestra Advisory Services LLC boosted its holdings in shares of iShares Biotechnology ETF by 7.8% during the fourth quarter. Kestra Advisory Services LLC now owns 42,306 shares of the financial services provider’s stock worth $7,140,000 after purchasing an additional 3,054 shares during the last quarter. The Manufacturers Life Insurance Company acquired a new stake in shares of iShares Biotechnology ETF during the fourth quarter worth $9,712,000. Finally, CANADA LIFE ASSURANCE Co boosted its holdings in shares of iShares Biotechnology ETF by 1.3% during the fourth quarter. CANADA LIFE ASSURANCE Co now owns 97,073 shares of the financial services provider’s stock worth $16,393,000 after purchasing an additional 1,249 shares during the last quarter. Institutional investors and hedge funds own 62.45% of the company’s stock.

iShares Biotechnology ETF Trading Up 0.1%

Shares of iShares Biotechnology ETF stock opened at $170.66 on Friday. iShares Biotechnology ETF has a twelve month low of $123.61 and a twelve month high of $179.64. The business’s fifty day moving average price is $170.28 and its 200 day moving average price is $170.65.

iShares Biotechnology ETF Cuts Dividend

The company also recently announced a quarterly dividend, which was paid on Friday, March 20th. Investors of record on Tuesday, March 17th were issued a $0.1218 dividend. The ex-dividend date was Tuesday, March 17th. This represents a $0.49 dividend on an annualized basis and a yield of 0.3%.

iShares Biotechnology ETF Company Profile

(Free Report)

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.